Faron, etusivu

releases and publications

Holding in Company

Regulatory

Inside Information: Faron Announces Positive Phase II results in higher-risk myelodysplastic syndrome

Regulatory

Inside Information: Faron enters into an up to EUR 35 million convertible bond arrangement and issues first tranche of bonds with a principal amount of EUR 15 million

Regulatory

Faron Announces Acceptance of Bexmarilimab Data for Oral Presentation at 2025 Annual MDS Foundation Congress

Board Changes

Regulatory

Results of the Annual General Meeting, Change of Directors, Decision of the Board meeting after the AGM

Regulatory

Shareholders’ Nomination Board updates its recommendation on the number of Board members to be elected and the persons proposed to be elected

Regulatory

Inside Information: FDA Grants Orphan Drug Designation for Bexmarilimab in MDS

Regulatory

NOTICE OF FARON PHARMACEUTICALS LTD’S ANNUAL GENERAL MEETING

Regulatory

Inside Information: Faron Receives Positive EMA Opinion on Orphan Drug Designation for Bexmarilimab for the treatment of myelodysplastic syndrome (MDS)

Regulatory
Next
Back to top